Antiverse
LLM & Generative AI · Biologics & Biosimilars
$15.7Mtotal raised · 15 rounds on record
Venture roundlatest round · Jun 2026 · 5 mo ago
4backers · Deep Science Ventures, Future Planet Capital
$793kgrants · 2 grants · CORDIS
Overview
Antiverse combines generative AI and advanced antibody discovery to design functional, developable biologics for challenging drug targets.
Key facts
These are the key facts about Antiverse on Alion as of Nov 13, 2026. It was founded in 2017. It has raised $15.7M in 3 funding rounds. The latest round is Series A of $9.3M, announced in 2026.
- Founded
- 2017Alion company profile, updated Sep 28, 2026
- Total raised
- $15.7MSum of 3 equity rounds Alion knows
- Latest round
- Series A · $9.3M · Mar 3, 2026Press report · pulse2.com
Official records
Funding and backers
Total raised
$15.7M
15 rounds on record
Latest round
Venture round
Jun 2026 · 5 mo ago
Grants
$793k
2 grants · CORDIS
Backers
4
Deep Science Ventures, Future Planet Capital
The money's age
Fresh money
5 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 5
Raised a round Venture round
Mar 3
Raised a round Series A $9.3M · Pulse 2.0
Feb 27
Raised a round Venture round
Oct 15, 2024
Raised a round Seed $4.4M · businesswire
Oct 14, 2024
Raised a round Venture round
Jun 13, 2024
Raised a round Venture round
Mar 15, 2021
Raised a round Seed $2M · pharmaphorum
Jan 26, 2021
Raised a round Venture round
Jul 8, 2020
Raised a round Venture round
Jul 1, 2020
Won a grant $704k · CORDIS
Jan 16, 2020
Raised a round Venture round
Oct 1, 2018
Won a grant $89k · CORDIS
Aug 8, 2018
Raised a round Venture round
Jan 24, 2018
Raised a round Venture round
Jun 14, 2017
Raised a round Venture round
2017
Founded
Tractionpublic signals, read monthly
Web presence
top 2%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jun 2026 | — | — | find-and-update.company-information.service.gov.uk |
| Series A | Mar 2026 | $9.3M | — | Pulse 2.0 |
| Venture round | Feb 2026 | — | — | find-and-update.company-information.service.gov.uk |
| Seed | Oct 2024 | $4.4M | — | businesswire |
| Venture round | Oct 2024 | — | — | find-and-update.company-information.service.gov.uk |
| Venture round | Jun 2024 | — | — | find-and-update.company-information.service.gov.uk |
| Seed | Mar 2021 | $2M | — | pharmaphorum |
| Venture round | Jan 2021 | — | — | find-and-update.company-information.service.gov.uk |
| Venture round | Jul 2020 | — | — | find-and-update.company-information.service.gov.uk |
| Grant | Jul 2020 | $704k | — | CORDIS |
| Venture round | Jan 2020 | — | — | find-and-update.company-information.service.gov.uk |
| Grant | Oct 2018 | $89k | — | CORDIS |
| Venture round | Aug 2018 | — | — | find-and-update.company-information.service.gov.uk |
| Venture round | Jan 2018 | — | — | find-and-update.company-information.service.gov.uk |
| Venture round | Jun 2017 | — | — | find-and-update.company-information.service.gov.uk |
Registers and programsofficial lists and records that name the company
| Legal entity | Antiverse Ltd | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Alloy Therapeutics democratizes access to antibody discovery and biologics discovery technology to enable and advance drug discovery in…
Invenra delivers high-quality antibody discovery and engineering solutions, including monoclonal, bispecific, and trispecific antibodies…
Explore Therapeutic Protein Libraries. For decades, therapeutic antibody discovery and optimization has been a shot in the Dark With the…
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality.
Leading the advancement of biologics for targeted immune regulation & restoration.
Find out more about Biodextris, your premier biologics development and manufacturing partner. Check out our cutting-edge solutions.
Financials
Total raised
$16.5M
Latest round
Venture - Series Unknown
Funding rounds
15
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2026 | — | Details |
| Series A | 2026 | $9.3M | Details |
| Venture - Series Unknown | 2026 | — | Details |
| Seed | 2024 | $4.4M | Details |
| Venture - Series Unknown | 2024 | — | Details |
| Venture - Series Unknown | 2024 | — | Details |
| Seed | 2021 | $2M | Details |
| Venture - Series Unknown | 2021 | — | Details |
| Venture - Series Unknown | 2020 | — | Details |
| Grant | 2020 | $704k | Details |
| Venture - Series Unknown | 2020 | — | Details |
| Grant | 2018 | $89k | Details |
| Venture - Series Unknown | 2018 | — | Details |
| Venture - Series Unknown | 2018 | — | Details |
| Venture - Series Unknown | 2017 | — | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
i&i BioVia a fund
Deep Science VenturesVia a fund
Cambridge AngelsVia a fund
Future Planet CapitalVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Welsh firm Antiverse raises funds for AI antibody platform
Cardiff's Antiverse has raised $9.3m to develop its AI-based design platform for antibodies against hard-to-reach targets like GPCRs and ion channels.
Read more
Report
Antiverse raises $9.3M Series A to scale AI-driven antibody
Antiverse funding, AI antibody discovery, biotech Series A Europe, computational drug discovery, therapeutic antibody design.
Read more
Report
Antiverse: $9.3 Million Raised For AI-Driven Antibody Development Targeting Undruggable Disease Targets
Antiverse, an AI-driven techbio company specializing in de novo antibody design for challenging drug targets, has raised $9.3 million in Series A financing to accelerate the development of therapeutic antibodies aimed at historically undruggable disease t
Read more
Report
Nxera Pharma and Antiverse to design antibodies targeting GPCRs
The multi-target collaboration will leverage Antiverse
Read more
Report
Antiverse: £3.5 Million Raised For Advancing GenAI-Based Antibody Design Platform
Antiverse, a tech company that is designing antibodies for challenging targets, today announced it had added £3.5 million ($4.6 million) to its seed funding.
Read more
Report
Antiverse Raises £3.5M ($4.6M) to Advance Generative AI Antibody Design Platform
Antiverse, a techbio company designing antibodies for challenging targets, today announced it has added £3.5M ($4.6M) to its seed funding. The investment wil...
Read more
Report
Welsh startup Antiverse raises $2m for antibody discovery toolkit
New biotech Antiverse has raised seed funding of £1.4 million ($2 million) to develop its artificial intelligence-based platform for discovering therapeutic antibodies. The Cardiff, Wales startup is combining machine learning and phage display techniques
Read more
Report
How to cite this page
Alion, "Antiverse: key facts", as of Nov 13, 2026. https://alion.io/company/antiverse
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0